Phase II trial of VP-16-213 in advanced ovarian carcinoma.
We have reevaluated the effectiveness of VP-16-213 in advanced ovarian carcinoma. Twenty-five patients with measurable disease were treated for 3 days every 2 weeks with an escalating dose of the oral preparation. Twenty-two percent of 23 evaluable patients responded including one complete response. The median duration of response was 20 weeks and median survival 32 weeks. Toxicity was mild. The response rate observed is relatively high in patients pretreated with cis-platinum. VP-16-213 deserves further study, especially in combination with cis-platinum.
D000284:Administration, Oral; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
D005047:Etoposide; D011034:Podophyllotoxin; D002945:Cisplatin